Cytokinetics Launches Ninth Annual Grant Program for Cardiovascular Patient Advocacy
Event summary
- Cytokinetics opened applications for its ninth annual Communications Grant Program, supporting patient advocacy groups focused on hypertrophic cardiomyopathy (HCM) and heart failure.
- The deadline for applications is October 2, 2026, with recipients to be announced in January 2027.
- Grants will fund communications, marketing, or outreach initiatives for eligible nonprofit organizations in the U.S., Canada, Europe, or the U.K.
- Recipients must submit an outcomes report by the end of 2027 to measure the impact of the funding.
- The program has no oversight of the funded projects, aligning with Cytokinetics' broader patient-centric strategy.
The big picture
Cytokinetics' Communications Grant Program underscores its commitment to patient advocacy, a strategic move as it advances its cardiovascular pipeline, including MYQORZO (aficamten) for hypertrophic cardiomyopathy. The program aligns with broader industry trends where biopharmaceutical companies increasingly invest in patient engagement to drive awareness and support for underserved communities. With the upcoming submission of a Supplemental New Drug Application for aficamten in Q4 2026, the grant program also serves as a tool to strengthen relationships with key patient advocacy groups.
What we're watching
- Strategic Alignment
- How Cytokinetics' grant program reinforces its patient-centric approach amid regulatory and clinical milestones for its cardiovascular pipeline.
- Execution Risk
- Whether the program's lack of oversight will impact the measurable outcomes of funded initiatives.
- Industry Trends
- The pace at which similar biopharmaceutical companies adopt patient advocacy support programs.